Advertisement
Loading...

ECS Botanics Holdings Ltd

ECS.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.005
$0.00(0.00%)
Australian Market opens in 5h 46m
Advertisement

ECS Botanics Holdings Ltd Fundamental Analysis

ECS Botanics Holdings Ltd (ECS.AX) shows weak financial fundamentals with a PE ratio of -1.44, profit margin of -21.87%, and ROE of -19.79%. The company generates $0.0B in annual revenue with weak year-over-year growth of -3.33%.

Key Strengths

Cash Position19.84%
PEG Ratio0.00
Current Ratio3.51

Areas of Concern

ROE-19.79%
Operating Margin-31.97%
We analyze ECS.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -13.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-13.8/100

We analyze ECS.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

ECS.AX struggles to generate sufficient returns from assets.

ROA > 10%
-13.97%

Valuation Score

Excellent

ECS.AX trades at attractive valuation levels.

PE < 25
-1.44
PEG Ratio < 2
0.00

Growth Score

Weak

ECS.AX faces weak or negative growth trends.

Revenue Growth > 5%
-3.33%
EPS Growth > 10%
-3.75%

Financial Health Score

Excellent

ECS.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.43
Current Ratio > 1
3.51

Profitability Score

Weak

ECS.AX struggles to sustain strong margins.

ROE > 15%
-1979.46%
Net Margin ≥ 15%
-21.87%
Positive Free Cash Flow
No

Key Financial Metrics

Is ECS.AX Expensive or Cheap?

P/E Ratio

ECS.AX trades at -1.44 times earnings. This suggests potential undervaluation.

-1.44

PEG Ratio

When adjusting for growth, ECS.AX's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values ECS Botanics Holdings Ltd at 0.28 times its book value. This may indicate undervaluation.

0.28

EV/EBITDA

Enterprise value stands at 0.86 times EBITDA. This is generally considered low.

0.86

How Well Does ECS.AX Make Money?

Net Profit Margin

For every $100 in sales, ECS Botanics Holdings Ltd keeps $-21.87 as profit after all expenses.

-21.87%

Operating Margin

Core operations generate -31.97 in profit for every $100 in revenue, before interest and taxes.

-31.97%

ROE

Management delivers $-19.79 in profit for every $100 of shareholder equity.

-19.79%

ROA

ECS Botanics Holdings Ltd generates $-13.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.97%

Following the Money - Real Cash Generation

Operating Cash Flow

ECS Botanics Holdings Ltd generates limited operating cash flow of $-3.50M, signaling weaker underlying cash strength.

$-3.50M

Free Cash Flow

ECS Botanics Holdings Ltd generates weak or negative free cash flow of $-4.78M, restricting financial flexibility.

$-4.78M

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

ECS.AX converts -73.79% of its market value into free cash.

-73.79%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.44

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.003

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.28

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.31

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.43

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.51

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.20

vs 25 benchmark

ROA

Return on assets percentage

-0.14

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How ECS.AX Stacks Against Its Sector Peers

MetricECS.AX ValueSector AveragePerformance
P/E Ratio-1.4429.00 Better (Cheaper)
ROE-19.79%721.00% Weak
Net Margin-21.87%-53024.00% (disorted) Weak
Debt/Equity0.430.38 Neutral
Current Ratio3.514.01 Strong Liquidity
ROA-13.97%-19875.00% (disorted) Weak

ECS.AX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews ECS Botanics Holdings Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

808.64%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

50.73%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

31.92%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ